The rate of obesity in the US has been increasing for decades, but in 2023 they fell – at least due to the popularity of “miracle drug” semglutide. Approved for the treatment of obesity only in 2021, it is in low supply and is very expensive, but it has already had an extraordinary effect (“Semaglutide and similar medicines work”Below).
Still it can only be started. Many companies run for rival versions of semaglutide in cheap and easy-to-tech forms, as well as growing evidence that GLP-1 drugs can target a host of health conditions, treatment may have an effect which can be beyond the trend of growing obesity and possibly can also put the rights in the sale of alcohol. So what is next for these medicines – and what are you stumbling?
This article is part of a special series investigating the GLP-1 agonist boom. Read more here.
The increasing number of studies shows that apart from weight loss of semaglutide, there are many beneficial effects. For example, in A FourTesting that involving around 18,000 people had a heart attack or stroke compared to 8 percent of the 6.5 percent of the people receiving a placebo on Semaglutide.
Treatment can also reduce many types of craving, not only for food (see what GLP-1 drugs actually tell us about the reward system of the brain?). “There are reports of people to reduce people’s alcohol intake, which are largely reduced on semaglutide,” Helen Kolehoun At the University of Edinburgh, in Britain. “I think it is one of the exciting capacity …
